Form 4: ANI Pharmaceuticals Executive Sells Shares

Meredith Cook, Senior VP and General Counsel at ANI Pharmaceuticals, sold 500 shares of common stock.

Summary

• Meredith Cook, Senior VP, General Counsel & Secretary of ANI Pharmaceuticals, Inc. (ANIP), sold 500 shares of common stock.
• The transaction occurred on June 12, 2026, at a price of $82.03 per share.
• Following the transaction, the reporting person maintains beneficial ownership of 77,890 shares.
• The sale was executed under a pre-established Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard administrative practice.

Positives

• The transaction was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• General market risks associated with pharmaceutical equity holdings.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice among pharmaceutical executives and typically does not signal a change in company fundamentals or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Key Dates

Keywords

ANIP, ANI Pharmaceuticals, Insider Trading, Form 4, Stock Sale, Executive Compensation